Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rouvax
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Rouvax is a live attenuated measles virus vaccine indicated for the prevention of measles in children from 9 months of age. It is administered as a suspension for injection, reconstituted from powder and diluent, and can be given subcutaneously or intramuscularly. The vaccine contains live attenuated measles virus and is designed to stimulate an immune response that confers protection against future infection by the wild-type measles virus. Rouvax should not be used in individuals with true allergy to egg protein, known allergy to any constituent of the vaccine, previous allergic reaction to a similar vaccine, congenital or acquired immune deficiency (except certain HIV-infected children), or during pregnancy[7]. The primary indication is immunization against measles.
- Brand names
- Rouvax
- Other names
- measles virus vaccine (live)Schwarz strain measles vaccinelive attenuated measles vaccine
Beyond the preview
Go deeper on rouvax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rouvax.